By Ted Bosworth
Originally published by our sister publication, Clinical Oncology News
In patients with resected stage IIB or IIC melanoma, adjuvant pembrolizumab (Keytruda, Merck) significantly reduces the risk for disease recurrence, according to a multinational phase 3 trial.
Side effects were deemed manageable, and the researchers reported that quality of life—which was assessed as part of the trial protocol—was maintained.